Maynard Um
-
-
-
-
-
-
-
Rocket Pharmaceuticals board member Pedro Granadillo resigns
-
-
-
-
-
-
-
Goldman Sachs Reiterates Sell Rating on Rocket Pharmaceuticals (RCKT), PT $2,
-
-
-
-
-
-
-
Rocket Pharmaceuticals cuts workforce 30% to focus on heart treatments
-
-
-
-
-
-
-
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RCKT
-
-
-
-
-
-
-
RCKT INVESTOR DEADLINE: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
-
-
-
-
-
-
-
RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
-
-
-
-
-
-
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RCKT
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

